Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.
Hepatitis C virus (HCV) infected patients with vasculitis are often treated with the B-cell-depleting anti-CD20 antibody rituximab. Treatment reduces the cryoglobulins that cause vasculitis, yet it also leads to a transient increase in liver enzymes and HCV genomic RNA in the periphery. The mechanis...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0025789&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849470302365417472 |
|---|---|
| author | Zania Stamataki Samantha Tilakaratne David H Adams Jane A McKeating |
| author_facet | Zania Stamataki Samantha Tilakaratne David H Adams Jane A McKeating |
| author_sort | Zania Stamataki |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) infected patients with vasculitis are often treated with the B-cell-depleting anti-CD20 antibody rituximab. Treatment reduces the cryoglobulins that cause vasculitis, yet it also leads to a transient increase in liver enzymes and HCV genomic RNA in the periphery. The mechanism underlying the increased viral load is unclear and both direct and indirect roles have been proposed for B cells in HCV infection. We previously reported that HCV can associate with B cells and can trans-infect hepatocytes. We established an in vitro assay to study the effect(s) of rituximab on B cell-associated HCV infectivity. Rituximab-mediated lysis of B cells in vitro increases the level of infectious HCV released from B cells. Our results, using a model where virus does not replicate in B cells, recapitulate observations seen in patients and may explain in part the rapid increase in blood HCV RNA observed after rituximab treatment. |
| format | Article |
| id | doaj-art-8632b540e40f4fbdb0f18b5b1eeb2e4b |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-8632b540e40f4fbdb0f18b5b1eeb2e4b2025-08-20T03:25:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0169e2578910.1371/journal.pone.0025789Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.Zania StamatakiSamantha TilakaratneDavid H AdamsJane A McKeatingHepatitis C virus (HCV) infected patients with vasculitis are often treated with the B-cell-depleting anti-CD20 antibody rituximab. Treatment reduces the cryoglobulins that cause vasculitis, yet it also leads to a transient increase in liver enzymes and HCV genomic RNA in the periphery. The mechanism underlying the increased viral load is unclear and both direct and indirect roles have been proposed for B cells in HCV infection. We previously reported that HCV can associate with B cells and can trans-infect hepatocytes. We established an in vitro assay to study the effect(s) of rituximab on B cell-associated HCV infectivity. Rituximab-mediated lysis of B cells in vitro increases the level of infectious HCV released from B cells. Our results, using a model where virus does not replicate in B cells, recapitulate observations seen in patients and may explain in part the rapid increase in blood HCV RNA observed after rituximab treatment.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0025789&type=printable |
| spellingShingle | Zania Stamataki Samantha Tilakaratne David H Adams Jane A McKeating Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS ONE |
| title | Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. |
| title_full | Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. |
| title_fullStr | Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. |
| title_full_unstemmed | Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. |
| title_short | Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. |
| title_sort | rituximab treatment in hepatitis c infection an in vitro model to study the impact of b cell depletion on virus infectivity |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0025789&type=printable |
| work_keys_str_mv | AT zaniastamataki rituximabtreatmentinhepatitiscinfectionaninvitromodeltostudytheimpactofbcelldepletiononvirusinfectivity AT samanthatilakaratne rituximabtreatmentinhepatitiscinfectionaninvitromodeltostudytheimpactofbcelldepletiononvirusinfectivity AT davidhadams rituximabtreatmentinhepatitiscinfectionaninvitromodeltostudytheimpactofbcelldepletiononvirusinfectivity AT janeamckeating rituximabtreatmentinhepatitiscinfectionaninvitromodeltostudytheimpactofbcelldepletiononvirusinfectivity |